These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 16249086)
1. Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. Koziol JA; Wagner S; Sobel DF; Feng AC; Adams HP J Clin Neurosci; 2005 Nov; 12(8):895-901. PubMed ID: 16249086 [TBL] [Abstract][Full Text] [Related]
2. New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients. Wagner S; Adams H; Sobel DF; Slivka LS; Sipe JC; Romine JS; Koziol JA Eur Neurol; 2000; 43(4):194-200. PubMed ID: 10828648 [TBL] [Abstract][Full Text] [Related]
3. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217 [TBL] [Abstract][Full Text] [Related]
4. T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis. Thaler C; Faizy TD; Sedlacik J; Holst B; Stürner K; Heesen C; Stellmann JP; Fiehler J; Siemonsen S AJNR Am J Neuroradiol; 2017 Feb; 38(2):264-269. PubMed ID: 28059711 [TBL] [Abstract][Full Text] [Related]
6. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis. Zivadinov R; Dwyer M; Barkay H; Steinerman JR; Knappertz V; Khan O J Neurol; 2015 Mar; 262(3):648-53. PubMed ID: 25542295 [TBL] [Abstract][Full Text] [Related]
8. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW; Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990 [TBL] [Abstract][Full Text] [Related]
9. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Barkhof F; de Jong R; Sfikas N; de Vera A; Francis G; Cohen J; Mult Scler; 2014 Nov; 20(13):1704-13. PubMed ID: 24812043 [TBL] [Abstract][Full Text] [Related]
10. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049 [TBL] [Abstract][Full Text] [Related]
11. T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients. Thaler C; Faizy T; Sedlacik J; Holst B; Stellmann JP; Young KL; Heesen C; Fiehler J; Siemonsen S PLoS One; 2015; 10(12):e0144693. PubMed ID: 26659852 [TBL] [Abstract][Full Text] [Related]
12. Evolution of acute "black hole" lesions in patients with relapsing-remitting multiple sclerosis. Kostic D; Dincic E; Jovanovski A; Kostic S; Rancic N; Georgievski-Brkic B; Misovic M; Koprivsek K Acta Neurol Belg; 2023 Jun; 123(3):831-838. PubMed ID: 35397094 [TBL] [Abstract][Full Text] [Related]
13. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Comi G; Filippi M; Wolinsky JS Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502 [TBL] [Abstract][Full Text] [Related]